{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T16:33:48Z","timestamp":1781886828285,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T00:00:00Z","timestamp":1635811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T00:00:00Z","timestamp":1635811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose\n<\/jats:title>\n                <jats:p>Multiparametric magnetic resonance imaging (mpMRI) is a well-established imaging method for localizing primary prostate cancer (PCa) and for guiding targeted prostate biopsies. [<jats:sup>18<\/jats:sup>F]DCFPyL positron emission tomography combined with MRI (PSMA-PET\/MRI) might be of additional value to localize primary PCa. The aim of this study was to assess the diagnostic performance of [<jats:sup>18<\/jats:sup>F]DCFPyL-PET\/MRI vs. mpMRI in tumour localization based on histopathology after robot-assisted radical-prostatectomy (RARP), also assessing biopsy advice for potential image-guided prostate biopsies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Thirty prospectively included patients with intermediate to high-risk PCa underwent [<jats:sup>18<\/jats:sup>F]DCFPyL-PET\/MRI and mpMRI prior to RARP. Two nuclear medicine physicians and two radiologists assessed tumour localization on [<jats:sup>18<\/jats:sup>F]DCFPyL-PET\/MRI and on mpMRI respectively, and gave a prostate biopsy advice (2 segments) using a 14-segment model of the prostate. The uro-pathologist evaluated the RARP specimen for clinically significant PCa (csPCa) using the same model. csPCa was defined as any PCa with Grade Group (GG)\u2009\u2265\u20092. The biopsy advice based on imaging was correlated with the final histology in the RARP specimen for a total-agreement analysis. An additional near-agreement correlation was performed to approximate clinical reality.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Overall, 142 of 420 (33.8%) segments contained csPCa after pathologic examination. The segments recommended for targeted biopsy contained the highest GG PCa segment in 27\/30 patients (90.0%) both for [<jats:sup>18<\/jats:sup>F]DCFPyL-PET\/MRI and mpMRI. Areas under the receiver operating characteristics curves (AUC), sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for the total-agreement detection of csPCa per segment using [<jats:sup>18<\/jats:sup>F]DCFPyL-PET\/MRI were 0.70, 50.0%, 89.9%, 71.7%, and 77.9%, respectively. These results were 0.75, 54.2%, 94.2%, 82.8%, and 80.1%, respectively, for mpMRI only.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Both [<jats:sup>18<\/jats:sup>F]DCFPyL-PET\/MRI and mpMRI were only partly able to detect csPCa on a per-segment basis. An accurate detection (90.0%) of the highest GG lesion at patient-level was observed when comparing both [<jats:sup>18<\/jats:sup>F]DCFPyL-PET\/MRI and mpMRI biopsy advice with the histopathology in the RARP specimen. So, despite the finding that [<jats:sup>18<\/jats:sup>F]DCFPyL-PET\/MRI adequately detects csPCa, it does not outperform mpMRI.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00259-021-05604-9","type":"journal-article","created":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T04:29:44Z","timestamp":1635827384000},"page":"1731-1742","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Prospective analysis of clinically significant prostate cancer detection with [18F]DCFPyL PET\/MRI compared to multiparametric MRI: a comparison with the histopathology in the radical prostatectomy specimen, the ProStaPET study"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2524-2538","authenticated-orcid":false,"given":"Yves J. L.","family":"Bodar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben G. J. C.","family":"Zwezerijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"van der Voorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard H. E.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth S.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrine Q.","family":"Kol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennie","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelijne","family":"de Bie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maqsood","family":"Yaqub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bert A. D.","family":"Windhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry N. H.","family":"Hendrikse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 N.","family":"Vis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela E.","family":"Oprea-Lager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,2]]},"reference":[{"key":"5604_CR1","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","volume":"79","author":"N Mottet","year":"2021","unstructured":"Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, de Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79:243\u201362. https:\/\/doi.org\/10.1016\/j.eururo.2020.09.042.","journal-title":"Eur Urol."},{"key":"5604_CR2","unstructured":"Mottet N, Bellmunt J, Briers E, Bolla M, Bourke L, Cornford P, et al. EAU \u2013 ESTRO \u2013 ESUR \u2013 SIOG guidelines on prostate cancer. Arnhem, The Netherlands.: EAU Guidelines Office.; 2020. p. Epub ahead of print."},{"key":"5604_CR3","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1016\/j.juro.2013.02.072","volume":"189","author":"MA Bjurlin","year":"2013","unstructured":"Bjurlin MA, Carter HB, Schellhammer P, Cookson MS, Gomella LG, Troyer D, et al. Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processing. J Urol. 2013;189:2039\u201346. https:\/\/doi.org\/10.1016\/j.juro.2013.02.072.","journal-title":"J Urol"},{"key":"5604_CR4","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1016\/j.juro.2008.01.049","volume":"179","author":"BR Lane","year":"2008","unstructured":"Lane BR, Zippe CD, Abouassaly R, Schoenfield L, Magi-Galluzzi C, Jones JS. Saturation technique does not decrease cancer detection during followup after initial prostate biopsy. J Urol. 2008;179:1746\u201350. https:\/\/doi.org\/10.1016\/j.juro.2008.01.049 (discussion 50).","journal-title":"J Urol."},{"key":"5604_CR5","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","volume":"378","author":"V Kasivisvanathan","year":"2018","unstructured":"Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. 2018;378:1767\u201377. https:\/\/doi.org\/10.1056\/NEJMoa1801993.","journal-title":"N Engl J Med"},{"key":"5604_CR6","doi-asserted-by":"publisher","unstructured":"Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: Treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2016. https:\/\/doi.org\/10.1016\/j.eururo.2016.08.002.","DOI":"10.1016\/j.eururo.2016.08.002"},{"key":"5604_CR7","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.eururo.2015.07.029","volume":"70","author":"M de Rooij","year":"2016","unstructured":"de Rooij M, Hamoen EH, Witjes JA, Barentsz JO, Rovers MM. Accuracy of magnetic resonance imaging for local staging of prostate cancer: a diagnostic meta-analysis. Eur Urol. 2016;70:233\u201345. https:\/\/doi.org\/10.1016\/j.eururo.2015.07.029.","journal-title":"Eur Urol"},{"key":"5604_CR8","doi-asserted-by":"publisher","DOI":"10.1159\/000478789","author":"O Fahmy","year":"2017","unstructured":"Fahmy O, Khairul-Asri MG, Hadi S, Gakis G, Stenzl A. The role of radical prostatectomy and radiotherapy in treatment of locally advanced prostate cancer: a systematic review and meta-analysis. Urol Int. 2017. https:\/\/doi.org\/10.1159\/000478789.","journal-title":"Urol Int"},{"key":"5604_CR9","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0094-0143(05)70161-0","volume":"28","author":"MH Sokoloff","year":"2001","unstructured":"Sokoloff MH, Brendler CB. Indications and contraindications for nerve-sparing radical prostatectomy. Urol Clin North Am. 2001;28:535\u201343.","journal-title":"Urol Clin North Am"},{"key":"5604_CR10","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/s1470-2045(10)70223-0","volume":"11","author":"M Bolla","year":"2010","unstructured":"Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 2010;11:1066\u201373. https:\/\/doi.org\/10.1016\/s1470-2045(10)70223-0.","journal-title":"Lancet Oncol"},{"key":"5604_CR11","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.humpath.2006.11.012","volume":"38","author":"S Perner","year":"2007","unstructured":"Perner S, Hofer MD, Kim R, Shah RB, Li H, Moller P, et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol. 2007;38:696\u2013701. https:\/\/doi.org\/10.1016\/j.humpath.2006.11.012.","journal-title":"Hum Pathol"},{"key":"5604_CR12","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/pcan.2016.13","volume":"19","author":"SP Rowe","year":"2016","unstructured":"Rowe SP, Gorin MA, Allaf ME, Pienta KJ, Tran PT, Pomper MG, et al. PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges. Prostate Cancer Prostatic Dis. 2016;19:223\u201330. https:\/\/doi.org\/10.1038\/pcan.2016.13.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"5604_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00259-013-2525-5","volume":"41","author":"A Afshar-Oromieh","year":"2014","unstructured":"Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET\/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41:11\u201320. https:\/\/doi.org\/10.1007\/s00259-013-2525-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5604_CR14","doi-asserted-by":"publisher","DOI":"10.1097\/rct.0000000000001116","author":"A Arslan","year":"2020","unstructured":"Arslan A, Karaarslan E, G\u00fcner AL, Sa\u011flican Y, Tuna MB, \u00d6zi\u015fik O, et al. Comparison of MRI, PSMA PET\/CT, and fusion PSMA PET\/MRI for detection of clinically significant prostate cancer. J Comput Assist Tomogr. 2020. https:\/\/doi.org\/10.1097\/rct.0000000000001116.","journal-title":"J Comput Assist Tomogr"},{"key":"5604_CR15","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1148\/radiol.2019190687","volume":"293","author":"UJ Muehlematter","year":"2019","unstructured":"Muehlematter UJ, Burger IA, Becker AS, Schawkat K, H\u00f6tker AM, Reiner CS, et al. Diagnostic accuracy of multiparametric MRI versus (68)Ga-PSMA-11 PET\/MRI for extracapsular extension and seminal vesicle invasion in patients with prostate cancer. Radiology. 2019;293:350\u20138. https:\/\/doi.org\/10.1148\/radiol.2019190687.","journal-title":"Radiology"},{"key":"5604_CR16","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.euf.2016.10.002","volume":"4","author":"G Bauman","year":"2018","unstructured":"Bauman G, Martin P, Thiessen JD, Taylor R, Moussa M, Gaed M, et al. [(18)F]-DCFPyL positron emission tomography\/magnetic resonance imaging for localization of dominant intraprostatic foci: first experience. Eur Urol Focus. 2018;4:702\u20136. https:\/\/doi.org\/10.1016\/j.euf.2016.10.002.","journal-title":"Eur Urol Focus"},{"key":"5604_CR17","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s00259-020-05025-0","volume":"48","author":"L Evangelista","year":"2021","unstructured":"Evangelista L, Zattoni F, Cassarino G, Artioli P, Cecchin D, Dal Moro F, et al. PET\/MRI in prostate cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2021;48:859\u201373. https:\/\/doi.org\/10.1007\/s00259-020-05025-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5604_CR18","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/jama.280.11.969","volume":"280","author":"AV D'Amico","year":"1998","unstructured":"D\u2019Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969\u201374. https:\/\/doi.org\/10.1001\/jama.280.11.969.","journal-title":"JAMA"},{"key":"5604_CR19","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.2967\/jnumed.115.154336","volume":"56","author":"SP Rowe","year":"2015","unstructured":"Rowe SP, Gage KL, Faraj SF, Macura KJ, Cornish TC, Gonzalez-Roibon N, et al. (1)(8)F-DCFBC PET\/CT for PSMA-based detection and characterization of primary prostate cancer. J Nucl Med. 2015;56:1003\u201310. https:\/\/doi.org\/10.2967\/jnumed.115.154336.","journal-title":"J Nucl Med"},{"key":"5604_CR20","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/jlcr.3430","volume":"59","author":"HT Ravert","year":"2016","unstructured":"Ravert HT, Holt DP, Chen Y, Mease RC, Fan H, Pomper MG, et al. An improved synthesis of the radiolabeled prostate-specific membrane antigen inhibitor, [(18) F]DCFPyL. J Labelled Comp Radiopharm. 2016;59:439\u201350. https:\/\/doi.org\/10.1002\/jlcr.3430.","journal-title":"J Labelled Comp Radiopharm"},{"key":"5604_CR21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.eururo.2015.08.052","volume":"69","author":"JC Weinreb","year":"2016","unstructured":"Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur Urol. 2016;69:16\u201340. https:\/\/doi.org\/10.1016\/j.eururo.2015.08.052.","journal-title":"Eur Urol"},{"key":"5604_CR22","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00259-020-04934-4","volume":"48","author":"S Fanti","year":"2021","unstructured":"Fanti S, Goffin K, Hadaschik BA, Herrmann K, Maurer T, MacLennan S, et al. Consensus statements on PSMA PET\/CT response assessment criteria in prostate cancer. Eur J Nucl Med Mol Imaging. 2021;48:469\u201376. https:\/\/doi.org\/10.1007\/s00259-020-04934-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5604_CR23","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1007\/s00259-021-05245-y","volume":"48","author":"F Ceci","year":"2021","unstructured":"Ceci F, Oprea-Lager DE, Emmett L, Adam JA, Bomanji J, Czernin J, et al. E-PSMA: the EANM standardized reporting guidelines v10 for PSMA-PET. Eur J Nucl Med Mol Imaging. 2021;48:1626\u201338. https:\/\/doi.org\/10.1007\/s00259-021-05245-y.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"5604_CR24","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.clgc.2015.12.005","volume":"14","author":"FE von Eyben","year":"2016","unstructured":"von Eyben FE, Kiljunen T, Kangasmaki A, Kairemo K, von Eyben R, Joensuu T. Radiotherapy boost for the dominant intraprostatic cancer lesion-a systematic review and meta-analysis. Clin Genitourin Cancer. 2016;14:189\u201397. https:\/\/doi.org\/10.1016\/j.clgc.2015.12.005.","journal-title":"Clin Genitourin Cancer"},{"key":"5604_CR25","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.260232","author":"YJL Bodar","year":"2021","unstructured":"Bodar YJL, Koene BPF, Jansen BHE, Cysouw MCF, Meijer D, Hendrikse HNH, et al. Standardized uptake values are adequate measures of lesional (18)F-DCFPyL uptake in patients with low prostate cancer disease burden. J Nucl Med. 2021. https:\/\/doi.org\/10.2967\/jnumed.120.260232.","journal-title":"J Nucl Med"},{"key":"5604_CR26","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/pas.0000000000000530","volume":"40","author":"JI Epstein","year":"2016","unstructured":"Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: definition of grading patterns and proposal for a new grading system. The American journal of surgical pathology. 2016;40:244\u201352. https:\/\/doi.org\/10.1097\/pas.0000000000000530.","journal-title":"The American journal of surgical pathology"},{"key":"5604_CR27","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.189233","author":"C Kesch","year":"2017","unstructured":"Kesch C, Vinsensia M, Radtke JP, Schlemmer HP, Heller M, Ellert E, et al. Intra-individual comparison of 18F-PSMA-1007-PET\/CT, multi-parametric MRI and radical prostatectomy specimen in patients with primary prostate cancer - a retrospective, proof of concept study. J Nucl Med. 2017. https:\/\/doi.org\/10.2967\/jnumed.116.189233.","journal-title":"J Nucl Med"},{"key":"5604_CR28","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1007\/s00259-016-3346-0","volume":"43","author":"FL Giesel","year":"2016","unstructured":"Giesel FL, Sterzing F, Schlemmer HP, Holland-Letz T, Mier W, Rius M, et al. Intra-individual comparison of (68)Ga-PSMA-11-PET\/CT and multi-parametric MR for imaging of primary prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:1400\u20136. https:\/\/doi.org\/10.1007\/s00259-016-3346-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5604_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f2125","volume":"346","author":"HC de Vet","year":"2013","unstructured":"de Vet HC, Mokkink LB, Terwee CB, Hoekstra OS, Knol DL. Clinicians are right not to like Cohen\u2019s kappa. BMJ. 2013;346: f2125. https:\/\/doi.org\/10.1136\/bmj.f2125.","journal-title":"BMJ"},{"key":"5604_CR30","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1148\/radiol.2018180788","volume":"289","author":"RM Hicks","year":"2018","unstructured":"Hicks RM, Simko JP, Westphalen AC, Nguyen HG, Greene KL, Zhang L, et al. Diagnostic accuracy of (68)Ga-PSMA-11 PET\/MRI compared with multiparametric MRI in the detection of prostate cancer. Radiology. 2018;289:730\u20137. https:\/\/doi.org\/10.1148\/radiol.2018180788.","journal-title":"Radiology"},{"key":"5604_CR31","doi-asserted-by":"publisher","first-page":"012663","DOI":"10.1002\/14651858.CD012663.pub2","volume":"4","author":"FH Drost","year":"2019","unstructured":"Drost FH, Osses DF, Nieboer D, Steyerberg EW, Bangma CH, Roobol MJ, et al. Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. The Cochrane database of systematic reviews. 2019;4:012663. https:\/\/doi.org\/10.1002\/14651858.CD012663.pub2.","journal-title":"The Cochrane database of systematic reviews."},{"key":"5604_CR32","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.eururo.2015.12.053","volume":"70","author":"M Eiber","year":"2016","unstructured":"Eiber M, Weirich G, Holzapfel K, Souvatzoglou M, Haller B, Rauscher I, et al. Simultaneous (68)Ga-PSMA HBED-CC PET\/MRI improves the localization of primary prostate cancer. Eur Urol. 2016;70:829\u201336. https:\/\/doi.org\/10.1016\/j.eururo.2015.12.053.","journal-title":"Eur Urol"},{"key":"5604_CR33","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.cpet.2015.09.001","volume":"11","author":"H Herzog","year":"2016","unstructured":"Herzog H, Lerche C. Advances in clinical PET\/MRI instrumentation. PET clinics. 2016;11:95\u2013103. https:\/\/doi.org\/10.1016\/j.cpet.2015.09.001.","journal-title":"PET clinics"},{"key":"5604_CR34","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1007\/s11307-015-0826-8","volume":"17","author":"DE Oprea-Lager","year":"2015","unstructured":"Oprea-Lager DE, Yaqub M, Pieters IC, Reinhard R, van Moorselaar RJ, van den Eertwegh AJ, et al. A clinical and experimental comparison of time of flight PET\/MRI and PET\/CT systems. Mol Imaging Biol. 2015;17:714\u201325. https:\/\/doi.org\/10.1007\/s11307-015-0826-8.","journal-title":"Mol Imaging Biol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-021-05604-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-021-05604-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-021-05604-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T11:04:48Z","timestamp":1647947088000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-021-05604-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,2]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["5604"],"URL":"https:\/\/doi.org\/10.1007\/s00259-021-05604-9","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,2]]},"assertion":[{"value":"23 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the institutional research board of the Amsterdam UMC (location VUmc), and each participant provided informed consent to participate.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Each participant provided consent for data publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}